Summit Therapeutics Reports Stronger Survival Benefits for Lead Cancer Drug in Extended Follow-Up
Summit Therapeutics Inc. (SMMT) has released updated overall survival data from its Phase 3 HARMONi trial, showing improved outcomes with the investigational bispecific antibody ivonescimab combined with chemotherapy compared to placebo plus chemotherapy for EGFR-mutated non-squamous NSCLC patients previously treated with third-generation TKIs. The latest analysis revealed a hazard ratio of 0.76 in Western participants after 23.2 months of median follow-up, indicating stronger survival benefits than earlier results. The updated findings align the efficacy observed in Western and Asian patient groups, both showing consistent safety profiles without new adverse signals. Summit has submitted these data to the FDA as part of its Biologics License Application for ivonescimab, with a target action date set for November 14, 2026.
Tickers: $SMMT
Topics: bispecific_antibody lung_cancer oncology pharma